Master from Fudan University, Biology & MBA.
2016, awarded as "New and Glamorous Leader of the Year" by China Venture Capital Research Institute
2017, awarded as one of the "cutting-edge venture capital investors" by Securities Times.
He used to be Assistant General Manager of Beyond Diagnostics Co., Ltd.,
Investment Director of Suzhou Dragonrise Venture Capital Co., Ltd., and has over 10 years’ experience in the start-up, management and investment of the medical industry, with a total invested amount of more than 6 billion RMB.
Investment case: Danxia Biotechnology, Bioscience technology, Annoroad genetech, Vivachek, Huayin Health, Sino-Medi Gene, Harmony health, Linked biotech pathology, United-Imaging Medical.